XML 52 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2014
Jan. 01, 2018
Dec. 31, 2017
Revenue              
Accumulated Deficit $ (953,036)   $ (953,036)       $ (812,517)
Accounts receivable 3,175   3,175       $ 1,880
Revenue recognized from contract liabilities 0   1,500        
Revenues 941 $ 3,924 7,774 $ 9,287      
ASU 2014-09              
Revenue              
Accumulated Deficit           $ (1,300)  
Deferred revenue           (800)  
Accounts receivable           $ 500  
Product Development and Licensing Agreements              
Revenue              
Revenues 131 1,238 2,792 2,488      
Contracts and Grants              
Revenue              
Revenues 810 2,686 4,982 6,799      
Bristol-Myers Squibb Company | Product Development and Licensing Agreements              
Revenue              
Deferred revenue         $ 5,000    
Reimbursement of external costs (as percent)         50.00%    
Revenues 100   2,700        
IAVI & Frontier | Contracts and Grants              
Revenue              
Revenues 100 2,300 2,800 4,600      
Rockefeller | Contracts and Grants              
Revenue              
Revenues $ 500 $ 300 $ 1,800 $ 1,400